High Dependency Units Definitions - Pneumologia Veneto
Insufficienza Respiratoria Andrea Vianello Fisiopatologia e Terapia Intensiva Respiratoria Ospedale Universit di Padova Airway narrowing & obstruction Airway Inflammatio
n Shortene d muscles curvatur e muscle strength Frictional WOB AutoPEEP
Elastic WOB Gas trapping VT VA VE PaCO2 pH PaO2
VCO2 usa ii farmaci farmaci ee bene bene !! usa Airway Inflammatio n Steroids
Abx Shortene d muscles curvatur Teophylline e muscle strength Airway narrowing &
obstruction BDs AutoPEEP Elastic WOB Gas trapping VT
VA Frictional WOB VE PaCO2 pH PaO2 VCO2
usa ii farmaci farmaci ee bene bene !! usa Airway Inflammatio n Steroids Abx Shortene
d muscles curvatur Teophylline e muscle Airway narrowing & obstruction BDs
MV AutoPEEP VE MV VA PEEP Elastic WOB
Gas trapping VT strength Frictional WOB PaCO2 pH PaO2
MV VCO2 NonInvasive Ventilation a form of ventilatory support that avoids airway invasion Hill et al Crit Care Med 2007; 35:2402-7 NIV VS TRATTAMENTO STANDARD
Keenan S et al NIV VS TRATTAMENTO STANDARD Keenan S et al NIV - Meta-analysis (n=8) NPPV resulted in decreased mortality (RR 0.41; 95% CI 0.26, 0.64), decreased need for ETI (RR 0.42; 95%CI 0.31, 0.59)
Greater improvements within 1 hour in pH (WMD 0.03; 95%CI 0.02, 0.04), PaCO2 (WMD -0.40 kPa; 95%CI -0.78, -0.03), RR (WMD 3.08 bpm; 95%CI 4.26, -1.89). Complications associated with treatment (RR 0.32; 95%CI 0.18, 0.56) and length of hospital stay were also reduced with NPPV (WMD 3.24 days; 95%CI 4.42, -2.06) ghtowler, Elliott, Wedzicha & Ram BMJ 2003; 326:185 49 pazienti con IRA in BPCO dopo fallimento terapia medica, pH 7.2 Simili durata di permanenza in ICU, durata VM, complicanze
generali, mortalit in ICU, e mortalit in ospedale con NIV 48% evitano ETI, sopravvivono con permanenza in ICU inferiore vs pazienti VM invasiva (P=0.02) A 1 anno: NIV inferiore riospedalizzazione (65% vs 100% P=0.016) e minor frequenza di riutilizzo supplemento di ossigeno (0% vs 36%) Studio caso-controllo: 64 paz. con IRA trattati con NIV pH = 7.18 40/64 (62%) fallimento NIV (RR con NIV - 38%) Simili mortalit in ICU, e mortalit in ospedale; durata di permanenza in ICU e post ICU, ma: Inferiori complicanze (P=0.01) e probabilit di rimanenere in VM (P=0.056)
Se NIV efficace (24/64 = 38%) migliore sopravvivenza e ridotta permanenza in ICU vs pazienti VM invasiva NIV: Change in practice over time 1992-1996 (mean pH = 7.25+/0.07) 1997-1999 (7.20+/-0.08; P<0.001). > 1997 - risk of failure pH <7.25 three fold lower than in 19921996. > 1997 ARF with a pH >7.28 were treated in Medical Ward (20% vs 60%). Daily cost per patient treated
with NIV (558+/-8 vs 470+/14,P<0.01) Carlucci et al Intensive Care Med 2003; 3:419- Epidemiology Rationale: evidence supporting use of NIV varies widely for different causes of ARF. Population: 11,659,668 cases of ARF from the Nationwide Inpatient Sample during years 2000 to 2009; Objectives: To compare utilization
trends and outcomes associated with NIV in patients with and without COPD. Rationale: The patterns and outcomes of NIV use in patients hospitalized for AECOPD nationwide are unknown. Population: 7,511,267 admissions for acute AE occurred from 1998 to 2008; Objectives: To determine the prevalence and trends of NIV in AECOPD.
Use of NIPPV or IMV as first-line respiratory support in patients hospitalized with AECOPD Joint BTS/RCP London/Intensive Care Society Guidelines. NIV in When to use Non-Invasive Ventilation Goals of NIV can they be reached? NIV is time consuming, needs proper equipment, enough staff with sufficient expertise.
time technical equipmentstaff expertise predict success of NIV Eur Respir J 2002; 19: 115966 Definition of the three levels of care European Task Force on Respiratory Intermediate Care Survey Corrado et al, ERJ 2002;20:1343-50
Appropriatezza di utilizzo della Ventilazione NonInvasiva in ambito pneumologico nellassistenza ai pazienti con BroncoPneumopatia Cronica Ostruttiva in fase acuta. Rate of NIV failure is extremely different according to study design, severity of illness and level of monitoring Sixty-two RCTs including a total of 5870
patients Overall NIV failure: 16.3% NIV Real Life Evaluation of all 449 patients receiving NPPV for a 1-yr period for acute or acute on chronic RF CPE (n=97) AECOPD (n=87) non-COPD acute hypercapnic RF (n=35)
postextubation RF (n=95) acute hypoxemic RF (n=144) Intubation rate was 18%, 24%, 38%, 40%, and 60%, respectively Hospital mortality for patients with acute hypoxemic RF who failed NPPV was 64% Schettino G. Crit Care Med 2008; 36:441 The percentage of patients
transitioned from NIV to IMV 5% and did not increase from 1998 to 2008 Reasons for low rate of IMV use after NPPV, compared to clinical trial: End of life decision to not accept IMV Patients died before IMV could be started Good selection of appropriate patients
High mortality rate (30%) ; over time OR for death:1.63, compared to those initially on IMV hospital stay Nearly one third of patients for whom there is the best evidence base for NIV did not receive it Admission pH < 7.26: 66% received NIV compared to 34% pH 7.26 to 7.34. Similar lowest pH
Significant proportion had a metabolic acidosis Hospital mortality was 25% (270/1077) for patients receiving NIV but 39% (86/219) for those with late onset acidosis The audit raises concerns that challenge the respiratory community to lead appropriate clinical improvements across the acute sector Reasons for high mortality rate in patients transitioned to IMV Increased use of NIPPV in patients difficult to ventilate?
Continuation of NIPPV despite a lack of early improvement? Aetiology of NIV failure A. Failure to adequately ventilate/oxygenate A. Delayed NIV treatment B. Inappropriate ventilatory technique C. Patients clinical condition B. Dependence on non-invasive support
Lack of improvement of acute illness NIV failure is predicted by: - Advanced age - High acuity illness on admission (i.e. SAPS-II >34) - Acute respiratory distress syndrome - Community-acquired pneumonia with or without sepsis - Multi-organ system failure NIV in acute COPD: correlates for success NIV failure
Retrospective analysis 59 episodes of ARF in 47 COPD patients n=5 40 NIV success: 46 NIV failure: 13 Predictors for NIV failure: Higher PaCO2 at admission
0 Other Pneumonia Ambrosino N, Thorax 1995;50:755-7 NIV complications Complication
Incidenc e (%) Major Aspiration pneumonia Haemodinamyc collapse Barotrauma <5 Infrequen t Rare
Minor Noise CO2 rebreathing Discomfort 50-10 50-100 30-50 Claustrophobia 5-20
Nasal skin lesions 2-50 Mask selection - a crucial issue! CO2 rebreathing (50-100%) Noise (50-100%) Leak/Discomfort (30-50%) Claustrophobia (5-20%) Nasal skin lesions (2-50%) NIV should not be used in:
Respiratory arrest Inability to tolerate the device, because of claustrophobia, agitation or uncooperativeness Inability to protect the airway, due to swallowing impairment Excessive secretions not sufficiently managed by clearance techniques Recent upper airway surgery Transition to IMV: when is in the interest of a patient? Hospital mortality: 64% (Schettino, 2008) Mortality rate: 30%; prolonged
hospitalization (Chandra, 2011) Great hospital mortality (Walkey, 2013) Transition to IMV (personal experience, 2011-2013) Number of subjects Age (mean SD) , yrs Gender (males, females) 62 65.419.3 26, 36
Ineffective NIV, n (%) Severe hypercapnia Severe hypoxemia 52 (83.8) 25 (42.4) 21 (35.6) Dependence on NIV, n (%) 8 (13.3)
NIV complication, n (%) 2 (3.4) Tracheotomy, n (%) 16 (28.8) Outcome , n (%) Died during hosp Discharged from hosp 41 (66.1)
21 (33.9) Median survival: 46 days (95% CI, 43 to 162) Kaplan-Meier function of overall survival Mean survival: NM/CW =
305.5836.9 ] p=0.0176 COPD = 53.907.3 ] p<0.0001 ILD = 31.137.8 Kaplan-Meier function of survival according to baseline condition Median survival: 50 = 380.0 d (95%CI, 15.0 to n.c.) ] p=0.0071 >50 = 45.0 d (95%CI,24.0 to
54.0) Kaplan-Meier function of survival for dichotomus age (50 and >50) Remarks Mortality rate among patients transitioned to IMV is very high; The outcome of patients with ILD is extremely poor. Should IPF/COPD patients be excluded from IMV after failing a NIV trial?
Use of a novel veno-venous extracorporeal carbon dioxide removal system as an alternative to endotracheal intubation in a lung transplant candidate with acute respiratory failure. Submitted to Respiratory Care NIV in AECOPD: conclusions Confirm and reinforce the routine use of NIV, however:
Suggest caution with NIV among patients at high risk of failure The problem of transitioning from NIV to IMV: may not be in the interest of patients!
Users can draw electronically 3A-* 3A-* PS/2 Mouse Cordless Mouse Mouse PS/2- Most commonly used; connects to PS/2 port or USB port. ... Caused by continuous misuse of the body Many professions suffer from RSI who work for data entry...
Protein characterization (molecular mass, amino acid composition and sequence) Working with proteins 1. based on molecular size - dialysis and ultrafiltration - density gradient centrifugation - size-exclusion chromatography) 2. based on solubility of proteins - izoelectric precipitation - salting out...
Part of the wider Arbury Camp major residential development. ... Orchard Park Community Council. Cohousing and self build groups, i.e., potential purchasers. Funders such as brokers and building societies. ... K1 Cambridge Cohousing
The Defining Characteristics 12th-15th century (1100-1400) Earlier romances in verse (poetic form) Later ones sometimes in prose (NOT poetry) Tales of courtly love and chivalric adventure Based on feudal ideal of chivalry Code of Chivalry: Emphasizes courage, grace, honor, love,...
2. Meteorite impact causes multiple natural disasters Evidence of a Meteorite Layer of Iridium in rock layers Cenozoic 65 mya- present "Age of the Mammals" Life: Large mammals appear, Humans appear Ice Ages occur and ice sheets advance * Mammals...